No Carolina / NY / Florida
Ph: 561.316.3330

Aesculap, Inc. Receives 510(k) Clearance for Aesculap Aeos® Robotic Digital Microscope DIR800 Capability

DIR800 Allows for 3D Digital Infrared Fluorescence-Guided Surgery

Editor: What To Know

  • The company notes the DIR800 is an accessory for the Aesculap Aeos Robotic Digital Microscope, powered by True Digital Surgery, and is used in viewing intraoperative blood flow in the cerebral vascular area including, but not limited to, assessing cerebral aneurysm and vessel branch occlusion, as well as patency in neurosurgery.
  • DIR800 combines infrared fluorescence technology with 3D digital visualization while also allowing the surgeon and OR team to share the same high-quality live view and slow motion playback on multiple 3D 4K monitors.
  • Another key benefit is heads-up positioning to free the surgeon from the microscope ocular tether, allowing the surgeon, not the microscope, to dictate ergonomics.

Aesculap, Inc. announced today its receipt of FDA 510(k) clearance for DIR800 3D digital infrared fluorescence for use with its Aesculap Aeos Robotic Digital Microscope. This clearance further enhances the fluorescence capabilities of the microscope which already includes DUV400 3D digital ultraviolet mode.

The company notes the DIR800 is an accessory for the Aesculap Aeos Robotic Digital Microscope, powered by True Digital Surgery, and is used in viewing intraoperative blood flow in the cerebral vascular area including, but not limited to, assessing cerebral aneurysm and vessel branch occlusion, as well as patency in neurosurgery. It also aids in the visual assessment of intraoperative blood flow and vessel patency in bypass neurosurgical procedures.

With DIR800, the Aesculap Aeos Robotic Digital Microscope produces excitation light to illuminate the fluorescence properties of Indocyanine Green (ICG). The generated fluorescence signal depicts the distribution of the infrared dye in the patient’s blood vessels during surgery.

DIR800 combines infrared fluorescence technology with 3D digital visualization while also allowing the surgeon and OR team to share the same high-quality live view and slow motion playback on multiple 3D 4K monitors. Backlight illumination aids visualization of nearby non-fluorescing structures without the need to switch back to white light.

Another key benefit is heads-up positioning to free the surgeon from the microscope ocular tether, allowing the surgeon, not the microscope, to dictate ergonomics.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy